EE200100025A - Restenoosi ravi - Google Patents

Restenoosi ravi

Info

Publication number
EE200100025A
EE200100025A EEP200100025A EEP200100025A EE200100025A EE 200100025 A EE200100025 A EE 200100025A EE P200100025 A EEP200100025 A EE P200100025A EE P200100025 A EEP200100025 A EE P200100025A EE 200100025 A EE200100025 A EE 200100025A
Authority
EE
Estonia
Prior art keywords
treatment
restenosis
accetpabel
bisphosphonate
pyrophosphate
Prior art date
Application number
EEP200100025A
Other languages
English (en)
Estonian (et)
Inventor
Golomb Gershon
Daneberg Haim
Original Assignee
Yissum Research Development Company of the HebrewUniversity ofJerusalem
Hedasit Medical Research Services & Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company of the HebrewUniversity ofJerusalem, Hedasit Medical Research Services & Development Limited filed Critical Yissum Research Development Company of the HebrewUniversity ofJerusalem
Publication of EE200100025A publication Critical patent/EE200100025A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
EEP200100025A 1998-07-14 1999-07-14 Restenoosi ravi EE200100025A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12533698A IL125336A0 (en) 1998-07-14 1998-07-14 Compositions for inhibition and treatment of restinosis
PCT/IL1999/000387 WO2000003677A2 (fr) 1998-07-14 1999-07-14 Traitement de la restenose

Publications (1)

Publication Number Publication Date
EE200100025A true EE200100025A (et) 2002-06-17

Family

ID=11071743

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100025A EE200100025A (et) 1998-07-14 1999-07-14 Restenoosi ravi

Country Status (17)

Country Link
US (1) US6719998B1 (fr)
EP (2) EP1468691B1 (fr)
JP (4) JP4663116B2 (fr)
KR (1) KR20010074711A (fr)
CN (1) CN1321090A (fr)
AT (2) ATE262338T1 (fr)
AU (1) AU758882B2 (fr)
BR (1) BR9912066A (fr)
CA (1) CA2337175C (fr)
DE (2) DE69915834T2 (fr)
EE (1) EE200100025A (fr)
ES (2) ES2219028T3 (fr)
IL (3) IL125336A0 (fr)
NO (1) NO20010224L (fr)
PL (1) PL345782A1 (fr)
SK (1) SK472001A3 (fr)
WO (1) WO2000003677A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
EP1267888A4 (fr) * 2000-01-04 2005-12-28 Univ California Utilisation de bisphosphonates a faible dose pour inhiber la calcification cardiaque et arterielle
EP1372753B1 (fr) * 2001-02-16 2007-08-01 Abbott Laboratories Vascular Enterprises Limited Implants avec fk506 pour la prophylaxie et le traitement de la restenose
US6656506B1 (en) * 2001-05-09 2003-12-02 Advanced Cardiovascular Systems, Inc. Microparticle coated medical device
JP2006504749A (ja) * 2002-10-15 2006-02-09 ノバルティス アクチエンゲゼルシャフト アテローム性動脈硬化症の処置のためのビスホスホネートおよびそれらを含むデバイス
US8034361B2 (en) * 2002-11-12 2011-10-11 Advanced Cardiovascular Systems, Inc. Stent coatings incorporating nanoparticles
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
WO2005002545A1 (fr) * 2003-06-27 2005-01-13 Biorest Ltd. Procede de traitement du syndrome coronarien aigu
US20050153937A1 (en) * 2003-11-07 2005-07-14 Gershon Golomb Desensitization of compliment activation using monocyte/macrophage inhibitory compounds
CN100364544C (zh) * 2004-07-21 2008-01-30 上海第二医科大学附属瑞金医院 一种携带二氯亚甲基二膦酸的明胶微粒及制备方法
US7687482B2 (en) 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US7358361B2 (en) 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (fr) 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Composés bisphosphonates et procédés présentant un potentiel amélioré pour cibles multiples incluant fpps, ggpps, et dpps
WO2006087722A1 (fr) * 2005-02-17 2006-08-24 Hadasit Medical Research Services And Development Ltd. Bisphosphonates pour le traitement de l'endometriose
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
US20080181928A1 (en) * 2006-12-22 2008-07-31 Miv Therapeutics, Inc. Coatings for implantable medical devices for liposome delivery
US8802184B2 (en) 2007-05-30 2014-08-12 Abbott Cardiovascular Systems Inc. Medical devices containing biobeneficial particles
US20090099651A1 (en) * 2007-10-10 2009-04-16 Miv Therapeutics, Inc. Lipid coatings for implantable medical devices
US20090148491A1 (en) * 2007-12-05 2009-06-11 Abbott Cardiovascular Systems Inc. Dual-Targeted Drug Carriers
EP2255199A1 (fr) * 2008-02-19 2010-12-01 Jovesis Inc. Compositions de microparticules pour modifier des cellules favorisant le cancer
BRPI0915885A2 (pt) * 2008-07-09 2015-11-03 Univ Nebraska micelas funcionais para a liberação direcionada de substâncias químicas em tecido duro
US20130315981A1 (en) * 2010-06-25 2013-11-28 The Trustees Of Columbia University In The City Of New York Method for inducing fat loss in mammals
GB201200868D0 (en) * 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
EP2769741A1 (fr) * 2013-02-22 2014-08-27 Cardiatis S.A. Dispositif médical avec un revêtement biocompatible
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
AU2015258964B2 (en) 2014-05-16 2018-01-04 Oregon Health And Science University Use of bisphosphonates as HIV/AIDS adjunctive treatment
JP6910033B2 (ja) * 2016-08-01 2021-07-28 株式会社カネカ カルシプロテインパーティクルの吸着材、および吸着除去システムとその利用方法
CN106361701B (zh) * 2016-08-31 2019-08-27 上海交通大学 一种脂质体药物载体及其制备方法和应用
FR3068233A1 (fr) * 2017-07-03 2019-01-04 Omnium De Revalorisation Industrielle Odri Dispositif medical intra-arteriel et applications
JP6613290B2 (ja) 2017-11-28 2019-11-27 株式会社Ｓｕｂａｒｕ 運転アドバイス装置及び運転アドバイス方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
US4216211A (en) 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
WO1988000289A1 (fr) 1986-07-09 1988-01-14 Engine Technology Limited Segment de piston
CH675422A5 (fr) * 1988-03-31 1990-09-28 Symphar Sa
US5196409A (en) 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
IL91362A0 (en) 1989-08-20 1990-03-19 Yissum Res Dev Co Bisphosphonates,process for preparing them and pharmaceutical compositions containing them
PH27186A (en) 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
CA2042159A1 (fr) 1990-05-31 1991-12-01 Miguel A. Ondetti Methode de prevention de la restenose apres angioplastie faisant appel a un inhibiteur de l'enzyme de conversion de l'angiotensine
CA2124857A1 (fr) * 1991-11-11 1993-05-27 Howard C. Herrmann Methodes d'inhibition de la restenose
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FI92465C (fi) 1993-04-14 1994-11-25 Risto Tapani Lehtinen Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5652227A (en) 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5741514A (en) * 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
CN1304058C (zh) * 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
WO1997043437A2 (fr) * 1996-05-15 1997-11-20 The University Of Sheffield Inhibiteurs d'isopentenyle pyrophosphate isomerase (ipi) ou de prenyle transferase
KR100192215B1 (ko) 1996-09-03 1999-06-15 강재헌 3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
JP2001509176A (ja) * 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US5760030A (en) 1997-06-30 1998-06-02 Eli Lilly And Company Benzothiophene compounds and methods of use
US5932580A (en) 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
AU760703B2 (en) * 1998-01-29 2003-05-22 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
EP0998932A1 (fr) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Forme d'administration pharmaceutique contenant des diphosphonates ou leurs sels et méthode pour la fabriquer
US5932563A (en) 1998-10-23 1999-08-03 Ohio State Research Foundation Methods for treating spinal cord injury
EP1135397B1 (fr) 1998-12-10 2003-04-23 Aesgen, Inc. Methode de preparation du pamidronate de disodium
EP1210138A4 (fr) 1999-04-22 2003-05-07 Hydro Med Sciences Inc Administration regulee de bisphosphonates

Also Published As

Publication number Publication date
JP4663116B2 (ja) 2011-03-30
US6719998B1 (en) 2004-04-13
JP2011037871A (ja) 2011-02-24
JP2016041724A (ja) 2016-03-31
DE69942510D1 (de) 2010-07-29
JP5498342B2 (ja) 2014-05-21
IL142172A (en) 2007-07-24
EP1094820A2 (fr) 2001-05-02
KR20010074711A (ko) 2001-08-09
CA2337175C (fr) 2009-03-31
NO20010224D0 (no) 2001-01-12
NO20010224L (no) 2001-03-09
JP5903081B2 (ja) 2016-04-13
EP1468691A1 (fr) 2004-10-20
PL345782A1 (en) 2002-01-02
EP1468691B1 (fr) 2010-06-16
AU758882B2 (en) 2003-04-03
ATE471149T1 (de) 2010-07-15
CA2337175A1 (fr) 2000-01-27
SK472001A3 (en) 2001-09-11
EP1094820B1 (fr) 2004-03-24
DE69915834T2 (de) 2005-03-24
AU4646299A (en) 2000-02-07
JP2002520345A (ja) 2002-07-09
ATE262338T1 (de) 2004-04-15
JP6088619B2 (ja) 2017-03-01
DE69915834D1 (de) 2004-04-29
BR9912066A (pt) 2001-04-10
WO2000003677A2 (fr) 2000-01-27
WO2000003677A3 (fr) 2000-05-04
IL142172A0 (en) 2002-03-10
IL125336A0 (en) 1999-03-12
JP2013256524A (ja) 2013-12-26
ES2347553T3 (es) 2010-11-02
CN1321090A (zh) 2001-11-07
ES2219028T3 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
EE200100025A (et) Restenoosi ravi
CY1105517T1 (el) 2-oxo-1-pyrrolidine παραγωγο και οι φαρμακευτικες του χρησεις
NO975713D0 (no) Chelaterende polymere som kontrastmidler for medisinsk billeddannelse
DE69840645D1 (en) Benzamidinderivate
ES2185911T3 (es) Composiciones farmaceuticas que contienen polimeros de ortoester tamponados.
CU23088A3 (es) Compuestos de tetra-hidropiridina.
ITRM920734A1 (it) Composizioni per la stabilizzazione dei polimeri. (caso 153-5550)
FR2668697B1 (fr) Dissecteur, notamment pour chirurgie endoscopique.
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
ES2097181T3 (es) Composicion antidepresiva a base de nicotinamida-adenina-dinucleotido.
ITRM910052A1 (it) Procedimenti di modificazione chimica di polimeri ottenuti da acetone.
IT1303777B1 (it) Manipolo odontoiatrico per la polimerizzazione di composti oresine fotoindurenti.
ITTO930042A1 (it) Macchina germicida automatica per la sterilizzazione di qualsivoglia tipo di cornetta telefonica.
HK1018005A (en) Use of 2-(3,4-dimethoxycinnamoyl) aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis